Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 2/20 | 0.51 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.39 |
| ▸ | CHRNG | P07510 | 1/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | CHRND | Q07001 | 1/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25359743 | 1.00 | CALCRL (0.51) | CALCRLSSTR3FOLH1ITGB3ITGA2B | |
| SCHEMBL25360291 | 0.90 | CALCRL (0.44) | CALCRLSSTR3FOLH1ITGB3ITGA2B | |
| SCHEMBL25361531 | 0.88 | CALCRL (0.43) | CALCRLSSTR3FOLH1 | |
| SCHEMBL25361358 | 0.86 | HDAC8 (0.48) | HDAC8 | |
| SCHEMBL25438103 | 0.86 | CTSL (0.41) | CALCRLSSTR3PLGROCK2 | |
| SCHEMBL25361811 | 0.85 | FOLH1 (0.38) | CALCRLFOLH1 | |
| SCHEMBL25361472 | 0.85 | FOLH1 (0.38) | CALCRLFOLH1 | |
| SCHEMBL26015579 | 0.83 | ITGB1 (0.43) | CALCRLFOLH1HDAC8 | |
| SCHEMBL26024879 | 0.83 | CALCRL (0.42) | CALCRLFOLH1 | |
| SCHEMBL26024621 | 0.83 | FOLH1 (0.41) | CALCRLFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | CALCRL 3746/4885SSTR3 3591/4885FOLH1 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.